Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.

about

Downregulation of DNA repair proteins and increased DNA damage in hypoxic colon cancer cells is a therapeutically exploitable vulnerability.

P2860

Q45804371-E087C860-5499-4441-AB05-1B0D78D7D298

P2860

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.

Item

http://www.wikidata.org/entity/Q40038637

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Efficiency of olaparib in colo ...... the homologous repair protein.

@en

type

Item

label

Efficiency of olaparib in colo ...... the homologous repair protein.

@en

prefLabel

Efficiency of olaparib in colo ...... the homologous repair protein.

@en

P1476

Efficiency of olaparib in colo ...... the homologous repair protein.

@en

P2093

Corentin Richard

http://www.w3.org/2001/XMLSchema#string

Romain Boidot

http://www.w3.org/2001/XMLSchema#string

Sandy Chevrier

http://www.w3.org/2001/XMLSchema#string

P2860

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Global cancer statistics, 2002

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

Molecular views of recombination proteins and their control

Resistance to therapy caused by intragenic deletion in BRCA2

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.

P304

10680-10686

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.3748/WJG.V22.I48.10680

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Frédérique Végran

Francois Ghiringhelli

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28082821

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5192280

http://www.w3.org/2001/XMLSchema#string

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.

about

P2860

P2860

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932